CanSino Biologics Inc. (HKG: 6185)
Hong Kong
· Delayed Price · Currency is HKD
31.10
-0.40 (-1.27%)
Jan 2, 2025, 10:36 AM HKT
CanSino Biologics Employees
CanSino Biologics had 1,494 employees as of December 31, 2023. The number of employees decreased by 797 or -34.79% compared to the previous year.
Employees
1,494
Change (1Y)
-797
Growth (1Y)
-34.79%
Revenue / Employee
554.95K HKD
Profits / Employee
-533.88K HKD
Market Cap
11.32B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
BeiGene | 10,600 |
Hansoh Pharmaceutical Group Company | 9,123 |
JD Health International | 3,118 |
WuXi Biologics | 12,740 |
Sinopharm Group | 115,959 |
Innovent Biologics | 4,872 |
Sino Biopharmaceutical | 25,806 |
CSPC Pharmaceutical Group | 23,500 |
CanSino Biologics News
- 2 years ago - Riding Covid Vaccine Highs, CanSino Plans Swiss Listing - Seeking Alpha
- 2 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 2 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 2 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 2 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 2 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 3 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire
- 3 years ago - Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant - PRNewsWire